FY2025 EPS Forecast for Kyverna Therapeutics Cut by Analyst

Key Points

• HC Wainwright has revised Kyverna Therapeutics' FY2025 earnings estimate downward to ($3.60) per share, from a previous estimate of ($3.56), while maintaining a "Buy" rating and a $5.00 price target.
• Kyverna's latest earnings report showed an EPS of ($0.97) for the quarter, surpassing the consensus estimate of ($1.00) by $0.03.
• Institutional investors and hedge funds now hold 18.08% of Kyverna Therapeutics' stock, with significant recent purchases including Gilead Sciences acquiring a stake worth approximately $15.4 million.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Investment analysts at HC Wainwright dropped their FY2025 earnings per share (EPS) estimates for shares of Kyverna Therapeutics in a report issued on Wednesday, August 13th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($3.60) per share for the year, down from their previous forecast of ($3.56). HC Wainwright currently has a "Buy" rating and a $5.00 target price on the stock. The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics' Q4 2025 earnings at ($0.82) EPS and FY2026 earnings at ($3.61) EPS.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.03.

Kyverna Therapeutics Stock Performance

Shares of KYTX traded down $0.24 on Friday, reaching $3.30. The company's stock had a trading volume of 225,246 shares, compared to its average volume of 254,263. Kyverna Therapeutics has a 12-month low of $1.78 and a 12-month high of $8.78. The stock's 50 day simple moving average is $3.44 and its two-hundred day simple moving average is $2.79.

Hedge Funds Weigh In On Kyverna Therapeutics

Institutional investors have recently bought and sold shares of the stock. Gilead Sciences Inc. bought a new stake in Kyverna Therapeutics during the fourth quarter valued at about $15,432,000. Jacobs Levy Equity Management Inc. lifted its position in shares of Kyverna Therapeutics by 2,225.0% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 461,959 shares of the company's stock valued at $1,728,000 after buying an additional 442,090 shares in the last quarter. Peapod Lane Capital LLC bought a new position in shares of Kyverna Therapeutics during the 1st quarter valued at approximately $765,000. TD Asset Management Inc increased its holdings in Kyverna Therapeutics by 179.5% in the 2nd quarter. TD Asset Management Inc now owns 252,196 shares of the company's stock worth $774,000 after acquiring an additional 161,954 shares in the last quarter. Finally, Integral Health Asset Management LLC increased its holdings in Kyverna Therapeutics by 75.0% in the 4th quarter. Integral Health Asset Management LLC now owns 350,000 shares of the company's stock worth $1,309,000 after acquiring an additional 150,000 shares in the last quarter. 18.08% of the stock is owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.